US Proposal Could Halve Biocon's Biosimilar Development Costs

India’s Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.

Read original article